Columbia, Missouri, USA and Utrecht, the Netherlands
April 9th, 2020
Harry S. Truman Memorial Veterans’ Hospital’s research program is nationally recognized, in part, because of its Biomolecular Imaging Center (BIC). Using the latest imaging technology, researchers at Truman VA’s BIC conduct preclinical and translational studies to improve the lives of Veterans and all Americans through health care discovery and innovation. To further elevate current in vivo imaging capabilities, Truman VA has acquired a new, state-of-the-art multimodal imaging system, the MILabs VECTor PET/SPECT/OI/CT system*.
According to Timothy Hoffman, PhD, Director of Truman VA’s BIC, the synergistic capabilities of the fully integrated PET/SPECT/OI/CT system opens new dimensions in preclinical and translational imaging research. “The ability to image with each modality at ultra-high resolution is further enhanced by the simultaneous acquisition of dual-isotope PET/PET, multi-isotope PET/SPECT, alpha and beta radiotherapy, and three-dimensional tomographic bioluminescence and fluorescence images. We believe that such multimodal imaging advancements will help our ongoing research programs in Oncology, Cardiovascular Disease, and Traumatic Brain Injury (TBI) research so that we gain better insights into the basic mechanisms underlying what for many remains an ‘invisible’ injury.”
Dr. Frederik Beekman, CEO/CSO of MILabs and Professor at the Technical University of Delft, the Netherlands comments: “We are honored to deliver the first of our fully-loaded VECTor6 systems to Truman VA. One of the pre-eminent research institutions of the VA, which is one of the largest Federal Research Funding organizations in the US. Veterans disorders are more complex than ever before, and we are looking forward to working with the VA Biomolecular Imaging Center to ensure that its researchers can exploit the unique multimodal synergy capabilities of our VECTor platform.”
About Truman VA’s Biomolecular Imaging Center:
Truman VA’s BIC is a nationally recognized research facility within the medical center. Its mission is to facilitate discovery and innovation through state-of-the-art research. Truman VA researchers translate study findings to develop treatments that can be brought to the bedside for improved Veteran care. For more information, please visit: https://www.columbiamo.va.gov/services/Research.asp
About MILabs B.V.
This fast-growing Dutch company has a history of providing a continuum of innovations to expand the applications preclinical molecular imaging. With its latest adaptive platform, MILabs has succeeded at commercializing a scalable imaging platform, able to accommodate PET, SPECT, Optical and CT imaging either as stand-alone or fully integrated modalities on a single integrated system. For the commercialization of this preclinical imaging platform, MILabs was awarded the Commercial Innovation of the Year 2018 at the World Molecular Imaging Congress. For more information, visit: www.milabs.com or contact MILabs at [email protected]
*Reference herein to any specific commercial products, process, or service by trade name, trademark, manufacturer, or otherwise, does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Government and shall not be used for advertising or product endorsement purposes.
